Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Multiple Myeloma 26Lymphoma 22Leukemia, Myeloid, Acute 21Leukemia 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Hodgkin Disease 15Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 6Primary Myelofibrosis 5Neoplasms, Plasma Cell 5Myeloproliferative Disorders 5Recurrence 4Neuroblastoma 4Graft vs Host Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Polycythemia Vera 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Juvenile 3Ganglioneuroblastoma 3Thrombocythemia, Essential 2Testicular Neoplasms 2Rhabdomyosarcoma 2

Interventions

Ifosfamide 6X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5Doxorubicin 5Cyclophosphamide 5Vincristine 4Temozolomide 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Melphalan 4Thiotepa 3Irinotecan 3Biopsy 3Bevacizumab 3ulixertinib 2trioctyl phosphine oxide 2tipifarnib 2temsirolimus 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2cixutumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive, Peripheral × Stem Cell Transplantation × Clear all
NCT04530487 2025-06-29

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 7 charts
CNSSarcoma

Neuroblastoma, Rhabdomyosarcoma, Neuroectodermal Tumors, Primitive, Peripheral, Neurofibrosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡